Skip to main content Accessibility help
×
×
Home

Early technology assessment of new medical devices

  • Jan B. Pietzsch (a1) and M. Elisabeth Paté-Cornell (a2)
Abstract

Objectives: In the United States, medical devices represent an eighty-billion dollar a year market. The U.S. Food and Drug Administration rejects a significant number of applications of devices that reach the investigational stage. The prospects of improving patient condition, as well as firms' profits, are thus substantial, but fraught with uncertainties at the time when investments and design decisions are made. This study presents a quantitative model focused on the risk aspects of early technology assessment, designed to support the decisions of medical device firms in the investment and development stages.

Methods: The model is based on the engineering risk analysis method involving systems analysis and probability. It assumes use of all evidence available (both direct and indirect) and integrates the information through a linear formula of aggregation of probability distributions. The model is illustrated by a schematic version of the case of the AtrialShaper, a device for the reduction of stroke risk that is currently in the preprototype stage.

Results: The results of the modeling provide a more complete description of the evidence base available to support early-stage decisions, thus allowing comparison of alternative designs and management alternatives.

Conclusions: The model presented here provides early-stage decision-support to industry, but also benefits regulators and payers in their later assessment of new devices and associated procedures.

Copyright
References
Hide All
1. Barnett, HJM, Eliasziw, M, Meldrum, HE. Drugs and surgery in the prevention of ischemic stroke. N Engl J Med. 1995;332:238248.
2. Benjamin, JR, Cornell, CA. Probability, statistics, and decision for civil engineers. New York: McGraw-Hill; 1970.
3. Benjamin, EJ, Wolf, PA, D'Agostino, RB, et al. . Impact of atrial fibrillation on the risk of death—The Framingham Heart Study. Circulation. 1998;98:946952.
4. Berry, DA. Using a Bayesian approach in medical device development. Publication for the U.S. Federal Food and Drug Administration's Center for Devices and Radiological Health, Institute of Statistics & Decision Sciences and Comprehensive Cancer Center. Durham, NC: Duke University; 1997.
5. Buxton, M. Early assessment of health technologies - The state of the science. Presentation at CCOHTA/Euroscan Symposium ‘Early Assessment of Health Technologies’. Ottawa, Canada: October 12, 2000.
6. CCOHTA. CCOHTA/Euroscan Symposium on ‘Early Assessment of Health Technologies’. Conference Summary. Ottawa, Canada: Canadian Coordinating Office for Health Technology Assessment; 2000.
7. Clemen, RT. Combining forecasts: A review and annotated bibliography. Int J Forecast. 1989;5:559583.
8. Clemen, RT, Winkler, RL. Combining probability distributions from experts in risk analysis. Risk Anal. 1999;19:187203.
9. Clemens, PL. Making component failure probability estimates. Tutorial Paper; Jacobs Sverdrup; 2002.
10. Dmochowski, RR, Galen, D. Evaluation of subacute tissue response in an animal model to evaluate a novel therapy to treat stress urinary incontinence. Presentation at the International Continence Society 30th annual meeting. Tampere, Finland; 2000.
11. Eddy, DM. Clinical decision making—From theory to practice. London UK: Jones and Bartlett Publishers International; 1996.
12. Goodman, C. HTA: Providing a scientific basis for the commercialization of innovative, cost-effective technologies. Panel presentation; ISTAHC 2003. Canmore, Canada; June 24, 2003.
13. Hagen, A, Dintsios, CM, Perleth, M, et al. Methods for the assessment of premarket (pm) biomedical innovations: A systematic review. In: The challenge of collaboration. Proceedings of the 18th Annual Meeting of the International Society of Technology Assessment in Health Care, Berlin; June 2002.
14. Henley, EJ, Kumamoto, H. Probabilistic risk assessment. New York: IEEE Press; 1991.
15. Howard, RA, Matheson, JE. Influence diagrams. In: Howard, RA, Matheson, JE, eds. The principles and applications of decision analysis. Menlo Park CA: Strategic Decision Group; 1984.
16. Laupacis, A, Boysen, G, Connolly, S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med. 1994;154:14491457.
17. Murphy, DM, Paté-Cornell, ME. The SAM framework: Modeling the effects of management factors on human behavior in risk analysis. Risk Anal. 1996;16:501515.
18. Murray, JW. Health technology assessment: Providing a scientific basis for the commercialization of innovative, cost-effective technologies. Panel presentation; 19th Annual Meeting of the International Society of Technology Assessment in Health Care. Canmore, Canada; June 24, 2003.
19. Obrzut, SL, Hecht, P, Hayashi, K, Fanton, GS. The effect of radiofrequency energy on the length and temperature properties of the glenohumeral joint capsule. Arthroscopy. 1998;14:395400.
20. Pietzsch, JB, Paté-Cornell, ME, Krummel, TM. A framework for probabilistic assessment of new medical technologies. In: Spitzer, C, Schmocker, U, Dang, VN, eds. Probabilistic safety assessment and management (PSAM7-ESREL'04). Proceedings of the 7th International Conference on Probabilistic Safety Assessment and Management. London UK: Springer-Verlag; 2004:22242229.
21. Pietzsch, JB. Early-stage technology assessment: Methods and opportunities. Ital J Public Health 2005;2 (Suppl 1):7475.
22. Powell, NB, Riley, RW, Troell, RJ, et al. Radiofrequency volumetric reduction of the tongue: A porcine pilot study for the treatment of obstructive sleep apnea syndrome. Chest. 1997;111:13481355.
23. Powell, NB, Riley, RW, Troell, RJ, et al. Radiofrequency volumetric tissue reduction of the palate in subjects with sleep-disordered breathing. Chest. 1998;113:11631174.
24. Szczepura, A, Kankaanpää, J. An introduction to health technology assessment. In: Szczepura, A, Kankaanpää, J, eds. Assessment of health care technologies: Case studies, key concepts, and strategic issues. New York: John Wiley & Sons; 1996.
25. U.S. Nuclear Regulatory Commission. Reactor safety study: An assessment of accident risks in U.S. commercial nuclear power plants. US Nuclear Regulatory Commission, NUREG-75/014; 1975.
26. U.S. Food and Drug Administration. Guidance for the use of Bayesian statistics in medical device clinical trials. Guidance Document; Washington DC: FDA CDRH; May 2006.
27. von Neumann, J, Morgenstern, O. Theory of games and economic behavior. 3rd ed. Princeton, NJ: Princeton University Press; 1953.
Recommend this journal

Email your librarian or administrator to recommend adding this journal to your organisation's collection.

International Journal of Technology Assessment in Health Care
  • ISSN: 0266-4623
  • EISSN: 1471-6348
  • URL: /core/journals/international-journal-of-technology-assessment-in-health-care
Please enter your name
Please enter a valid email address
Who would you like to send this to? *
×

Keywords

Type Description Title
WORD
Supplementary materials

Pietzscha supplementary material 1
Pietzscha supplementary material 1

 Word (168 KB)
168 KB
WORD
Supplementary materials

Pietzscha supplementary material 2
Pietzscha supplementary material 2

 Word (81 KB)
81 KB

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed